For the Quarter Ending June 2026
Doxepin Hydrochloride Prices in North America
- In the United States, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q2 2026, driven by significant producer cost inflation.
- Doxepin Hydrochloride production costs increased, as the Producer Price Index (PPI) rose 5.5% year-over-year in June 2026.
- Demand for Doxepin Hydrochloride was supported by robust consumer spending, with retail sales growing 6.9% year-over-year in May 2026.
- The Doxepin Hydrochloride Price Index experienced upward pressure from rising fuel and material costs in Q2 2026, due to the Strait of Hormuz closure.
- The Doxepin Hydrochloride demand outlook remained optimistic in Q2 2026, supported by a low unemployment rate of 4.2% in June 2026.
- Overall inflation, reflected by a 3.5% year-over-year CPI increase in June 2026, contributed to higher Doxepin Hydrochloride production expenses.
- Supply chain disruptions and tariff adjustments contributed to increased Doxepin Hydrochloride production costs during Q2 2026.
- Industrial production growth of 0.7% year-over-year in June 2026 indicated sluggishness, impacting broader manufacturing stability.
Why did the price of Doxepin Hydrochloride change in June 2026 in North America?
- Producer costs for Doxepin Hydrochloride increased, with PPI rising 5.5% year-over-year in June 2026.
- Rising fuel and material costs in Q2 2026, influenced by Strait of Hormuz closure, pressured Doxepin Hydrochloride prices.
- Robust consumer spending, with retail sales up 6.9% year-over-year in May 2026, supported Doxepin Hydrochloride demand.
Doxepin Hydrochloride Prices in APAC
- In China, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q2 2026, influenced by rising input costs.
- Doxepin Hydrochloride production costs increased in June 2026, driven by a 4.1% rise in producer prices.
- Doxepin Hydrochloride demand outlook was subdued in June 2026, reflected by low consumer price index growth of 1.0%.
- Weak consumer spending, with retail sales growing only 1.0% in June 2026, indirectly impacted Doxepin Hydrochloride demand.
- China's Manufacturing Index expanded in June 2026, indicating a healthy industrial environment for Doxepin Hydrochloride supply.
- Industrial production in China increased by 5.3% in June 2026, supporting Doxepin Hydrochloride manufacturing capabilities.
- Crude oil imports into China plummeted in June 2026, reaching a decade low due to shipping disruptions.
- China's exports expanded significantly in Q2 2026, with commodity chemicals reaching record volumes in May 2026.
Why did the price of Doxepin Hydrochloride change in June 2026 in APAC?
- Rising input costs, with producer prices up 4.1% in June 2026, pressured Doxepin Hydrochloride prices.
- Subdued demand, with consumer prices up 1.0% in June 2026, limited Doxepin Hydrochloride price increases.
- Declining commodity prices in June 2026 partially eased production cost pressures for Doxepin Hydrochloride.
Doxepin Hydrochloride Prices in Europe
- In Germany, the Doxepin Hydrochloride Price Index rose in Q2 2026, driven by increased production costs and supply chain tensions.
- Production costs for Doxepin Hydrochloride increased as industrial producer prices rose 2.2% year-on-year in May 2026.
- Consumer price inflation, at 2.3% year-on-year in June 2026, contributed to cost-push pressure on Doxepin Hydrochloride.
- Demand for Doxepin Hydrochloride was supported by retail sales rising 1.8% year-on-year in May 2026.
- A stable 3.8% unemployment rate in May 2026 supported consumer ability to access healthcare and medications.
- Manufacturing activity contracted in June 2026, leading to supply constraints and higher operational costs.
- Supply chains remained tense in April and May 2026, exacerbated by Q2 2026 geopolitical tensions.
- Elevated energy costs, especially mineral oil products, climbed sharply in June 2026, increasing production expenses.
Why did the price of Doxepin Hydrochloride change in June 2026 in Europe?
- Increased industrial producer prices by 2.2% in May 2026 raised Doxepin Hydrochloride manufacturing costs.
- Tense supply chains and material shortages in Q2 2026 impacted Doxepin Hydrochloride production and availability.
- Elevated energy costs, particularly mineral oil products in June 2026, increased Doxepin Hydrochloride operational expenses.
For the Quarter Ending March 2026
Doxepin Hydrochloride Prices in North America
- In United States, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q1 2026, driven by surging precursor costs.
- The Doxepin Hydrochloride Production Cost Trend increased as the Producer Price Index rose 4.0% in March 2026.
- Consumer Price Index inflation of 3.3% in March 2026 elevated transportation expenses for Doxepin Hydrochloride supply chains.
- The Doxepin Hydrochloride Demand Outlook strengthened, supported by resilient retail sales growth of 4.0% in March 2026.
- A 4.3% unemployment rate and 91.8 consumer confidence in March 2026 sustained Doxepin Hydrochloride prescription access.
- Industrial production grew 0.7% in March 2026, preventing oversupply in the domestic Doxepin Hydrochloride market.
- The Manufacturing Index expanded in March 2026, ensuring steady packaging availability for Doxepin Hydrochloride formulations.
- Global naphtha and benzene feedstock costs spiked in March 2026, elevating Doxepin Hydrochloride manufacturing expenses.
- The Doxepin Hydrochloride Price Forecast indicated upward momentum in Q1 2026 as pharmaceutical producer prices strengthened.
Why did the price of Doxepin Hydrochloride change in March 2026 in North America?
- Surging global naphtha and benzene costs in March 2026 directly elevated Doxepin Hydrochloride production expenses.
- Middle East export disruptions in March 2026 severely restricted the availability of critical chemical precursors.
- Resilient retail sales and stable pharmaceutical shipments in February 2026 maintained strong baseline market demand.
Doxepin Hydrochloride Prices in APAC
- In China, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q1 2026, driven by surging upstream petrochemical costs.
- The Doxepin Hydrochloride Production Cost Trend increased in March 2026 as the PPI grew by 0.5%.
- The Doxepin Hydrochloride Demand Outlook remained stable in March 2026, supported by a 1.0% CPI increase.
- Industrial production grew by 5.7% in March 2026, ensuring ample Doxepin Hydrochloride supply for downstream formulation.
- Retail sales grew slowly by 1.7% in March 2026, reflecting softer consumer spending on discretionary pharmacy items.
- The urban unemployment rate reached 5.4% in March 2026, historically correlating with increased stress-related psychiatric prescriptions.
- Consumer confidence stood at 91.6 in February 2026, indicating cautious household spending on non-emergency healthcare treatments.
- The Manufacturing Index expanded in March 2026, reflecting robust production capabilities for pharmaceutical and fine chemical sectors.
- The Doxepin Hydrochloride Price Forecast trended upward in Q1 2026 as upstream naphtha feedstock costs rose sharply.
Why did the price of Doxepin Hydrochloride change in March 2026 in APAC?
- Upstream petrochemical and naphtha feedstock costs surged in Q1 2026 due to Middle East supply chain disruptions.
- Chinese chemical export volumes surged in March 2026, tightening domestic availability and driving up market valuations.
- Inquiries for phenol, a key feedstock, increased in Q1 2026 as regional production plants reduced operating capacity.
Doxepin Hydrochloride Prices in Europe
- In Germany, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q1 2026, driven by surging feedstock costs.
- Higher inflation at 2.7% in March 2026 increased operational costs, elevating the Doxepin Hydrochloride production cost trend.
- Producer prices declined by -0.2% in March 2026, indicating slightly eased upstream chemical precursor expenses.
- The Manufacturing Index expanded in March 2026, tightening the supply of shared industrial inputs for pharmaceutical packaging.
- Stagnant industrial production at 0.0% in February 2026 reflected flat baseline availability for bulk API synthesis capacity.
- Retail sales grew 0.7% and unemployment stayed at 4.2% in February 2026, sustaining the Doxepin Hydrochloride demand outlook.
- Negative consumer confidence at -24.7 in March 2026 caused cautious household spending, impacting outpatient psychiatric treatment applications.
- Pharmaceutical formulation demand strengthened across Europe in Q1 2026, supporting a firm Doxepin Hydrochloride price forecast.
Why did the price of Doxepin Hydrochloride change in March 2026 in Europe?
- Phenol feedstock costs for Doxepin Hydrochloride synthesis surged in Q1 2026 due to elevated electricity expenses.
- Phthalic anhydride feedstock costs spiked in March 2026 following surging upstream orthoxylene and mixed xylenes prices.
- Regional phenol feedstock supply tightened in Q1 2026 following major industry outages and permanent facility closures.
For the Quarter Ending December 2025
Doxepin Hydrochloride Prices in North America
- In the United States, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q4 2025, influenced by rising input costs and robust demand.
- Doxepin Hydrochloride production costs increased, driven by a 3.0% year-over-year rise in PPI in November 2025.
- Demand for Doxepin Hydrochloride was supported by a 3.3% year-over-year increase in retail sales in November 2025.
- A 2.7% year-over-year CPI increase in December 2025 indicated general inflation, raising raw material and energy costs.
- US Active Pharmaceutical Ingredients market expanded in 2025, bolstering Doxepin Hydrochloride demand.
- Industrial production increased 2.0% year-over-year in December 2025, supporting Doxepin Hydrochloride supply chain stability.
- Natural gas spot prices moved upward in late 2025 due to a December cold snap.
- Trade flows faced continuous change in 2025 due to geopolitical uncertainty and potential trade disputes.
- A 4.4% unemployment rate in December 2025 supported Doxepin Hydrochloride demand through increased healthcare access.
Why did the price of Doxepin Hydrochloride change in December 2025 in North America?
- Rising input costs, evidenced by a 3.0% PPI increase in November 2025, pressured Doxepin Hydrochloride prices.
- Strong consumer spending, with retail sales up 3.3% in November 2025, supported Doxepin Hydrochloride demand.
- Increased general inflation, shown by a 2.7% CPI rise in December 2025, contributed to higher production costs.
Doxepin Hydrochloride Prices in APAC
- In China, the Doxepin Hydrochloride Price Index fell quarter-over-quarter in Q4 2025, influenced by declining production costs and weak demand.
- Doxepin Hydrochloride production costs decreased in Q4 2025, as the Producer Price Index declined by 1.9% in December 2025.
- Aromatic hydrocarbon (benzene) and propylene feedstock costs faced bearish pressure in Q4 2025 due to oversupply.
- Doxepin Hydrochloride demand was constrained by weak consumer spending, with retail sales growing 0.9% in December 2025.
- China's Manufacturing Index expanded in December 2025, supporting stable supply chains for Doxepin Hydrochloride.
- Industrial Production grew by 5.2% in December 2025, indicating robust manufacturing activity for intermediate chemicals.
- The pharmaceutical industry in China experienced robust growth throughout 2025, propelled by an aging population.
- Europe-origin benzene cargoes emerged in Asia during November-December 2025, indicating surplus volumes.
Why did the price of Doxepin Hydrochloride change in December 2025 in APAC?
- Producer Price Index declined by 1.9% in December 2025, reducing manufacturing costs for Doxepin Hydrochloride.
- Aromatic hydrocarbon (benzene) and propylene feedstock costs faced bearish pressure in Q4 2025 due to oversupply.
- Weak consumer demand, with retail sales growing 0.9% in December 2025, impacted overall healthcare spending.
Doxepin Hydrochloride Prices in Europe
- In Germany, the Doxepin Hydrochloride Price Index experienced downward pressure in Q4 2025, influenced by declining producer prices.
- Doxepin Hydrochloride production costs faced persistent high energy and raw material costs throughout 2025.
- The Manufacturing Index contracted in December 2025, indicating a broader economic slowdown.
- Consumer confidence declined significantly to -17.5 in December 2025, reflecting widespread economic pessimism.
- The Doxepin Hydrochloride Price Index was influenced by a -2.5% PPI decrease in December 2025.
- Moderate inflation, with CPI at 1.8% in December 2025, contributed to increased Doxepin Hydrochloride operational costs.
- Industrial production grew by 0.8% in October 2025, supporting stable supply chains for Doxepin Hydrochloride.
- Retail sales increased by 1.1% in November 2025, indirectly supporting healthcare funding and access.
- A stable unemployment rate of 6.2% in December 2025 supported health insurance coverage for Doxepin Hydrochloride.
- Pharmaceutical industry growth increased in December 2025, supporting Doxepin Hydrochloride market stability.
Why did the price of Doxepin Hydrochloride change in December 2025 in Europe?
- Producer prices decreased by 2.5% in December 2025, reducing Doxepin Hydrochloride manufacturing input costs.
- Persistent high energy and raw material costs in 2025 maintained upward pressure on production.
- Increased German pharmaceutical output in December 2025 supported Doxepin Hydrochloride demand.
For the Quarter Ending September 2025
Doxepin Hydrochloride Prices in North America
- In the United States, the Doxepin Hydrochloride Price Index rose quarter-over-quarter in Q3 2025, driven by escalating production costs.
- Production costs increased due to a 2.6% PPI rise in August 2025 and higher Q3 2025 energy prices.
- Demand for Doxepin Hydrochloride was supported by strengthened US pharmaceutical market sentiment in Q3 2025.
- A 4.3% unemployment rate and 5.42% retail sales growth in September 2025 bolstered Doxepin Hydrochloride demand.
- Overall chemical demand weakened in Q3 2025, with new chemical orders declining, impacting broader supply.
- US tariffs on pharmaceutical imports and APIs contributed to inflationary effects on drug production costs in 2025.
- Chemical industry inventories shrank in Q3 2025 due to accelerating destocking, tightening supply.
- The Doxepin Hydrochloride price forecast indicates continued upward pressure from sustained input cost increases.
Why did the price of Doxepin Hydrochloride change in September 2025 in North America?
- Production costs rose from a 3.0% CPI increase in September 2025 and higher U.S. natural gas prices.
- Demand was supported by a low 4.3% unemployment rate in September 2025, increasing healthcare access.
- US tariffs on pharmaceutical imports in 2025 created inflationary effects on drug production expenses.
Doxepin Hydrochloride Prices in APAC
- In China, the Doxepin Hydrochloride Price Index fell quarter-over-quarter in Q3 2025, influenced by declining production costs and overcapacity.
- Doxepin Hydrochloride production costs decreased in Q3 2025, driven by a 2.3% year-on-year fall in PPI and lower feedstock costs.
- Doxepin Hydrochloride demand outlook remains stable, supported by a 3.0% year-on-year rise in retail sales in September 2025.
- Pharmaceutical market demand strengthened in Q3 2025, driven by an aging population and chronic diseases.
- Overall chemical industry demand weakened in Q3 2025, with manufacturing activity contracting in September 2025.
- Persistent chemical industry overcapacity in China during Q3 2025 intensified market competition.
- High inventories of 1,4-Butanediol in July 2025 created downward price pressure for related chemicals.
- The Doxepin Hydrochloride Price Index forecast suggests continued pressure due to ample supply and weak overall chemical demand.
Why did the price of Doxepin Hydrochloride change in September 2025 in APAC?
- Falling raw material costs, with PPI down 2.3% year-on-year in September 2025, reduced production expenses.
- Persistent chemical industry overcapacity in China during Q3 2025 intensified market competition.
- Weakening overall chemical industry demand in Q3 2025 impacted Doxepin Hydrochloride pricing.
Doxepin Hydrochloride Prices in Europe
- In Germany, the Doxepin Hydrochloride Price Index remained stable quarter-over-quarter in Q3 2025, influenced by softening producer prices.
- Doxepin Hydrochloride production costs saw mixed trends in Q3 2025, with producer prices declining 1.7% year-over-year in September 2025.
- Raw material costs for the German chemical industry remained elevated during Q3 2025, with CPI at 2.4% year-over-year in September 2025.
- Demand for Doxepin Hydrochloride was supported by an expanding pharmaceutical market and low 3.9% unemployment in September 2025.
- Low consumer confidence, at -23.6 index in September 2025, presented a bearish outlook for Doxepin Hydrochloride demand.
- Germany's Manufacturing Index contracted in September 2025, indicating a slowdown in overall industrial activity.
- Industrial production in Germany declined by 1.0% year-over-year in September 2025, affecting Doxepin Hydrochloride supply.
- Natural gas prices eased in Germany during Q3 2025, offering some relief to Doxepin Hydrochloride production costs.
Why did the price of Doxepin Hydrochloride change in September 2025 in Europe?
- Producer prices declined 1.7% year-over-year in September 2025, reducing Doxepin Hydrochloride manufacturing input costs.
- Germany's Manufacturing Index contracted in September 2025, signaling supply chain inefficiencies and higher costs.
- Low consumer confidence (-23.6 index in September 2025) tempered Doxepin Hydrochloride demand despite market expansion.
